Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors

被引:13
作者
Tan, Qing-quan [1 ]
Wang, Xing [1 ]
Yang, Le [1 ]
Chen, Yong-Hua [1 ]
Tan, Chun-lu [1 ]
Zhu, Xiao-mei [1 ]
Ke, Neng-wen [1 ]
Liu, Xu-Bao [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pancreat Surg, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
nonfunctional pancreatic neuroendocrine tumors; pancreatic neuroendocrine tumors; recurrence; ENETS CONSENSUS GUIDELINES; MANAGEMENT; NEOPLASMS; CLASSIFICATION; PREDICTORS; PROGNOSIS; SURVIVAL; UPDATE; SYSTEM;
D O I
10.1097/MD.0000000000020324
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although pancreatic neuroendocrine tumors (PNETs) are generally considered to have a favorable overall prognosis after resection, disease recurrence has been observed. Few studies have specifically addressed recurrence after resection of PNETs, especially for non-functioning PNETs (NF-PNETs). The aim of our study is to analyze the recurrence of resected well-differentiated NF-PNETs. Patients who underwent surgical resection for grade 1 and 2 NF-PNETs without synchronous metastasis were identified for analysis. Patients were treated from January 2009 to December 2017 in our institution. Univariate and multivariate cox regression analysis were conducted to identify prognostic factors. Of the 88 patients, 46 were men (52%) and the mean age was 52 years. With a median follow-up of 49.1 months (range, 8-122 months), there were 12 recurrences (14%). Liver was the most common recurrence site (7/12, 58%). The 1-, 3-, and 5-year recurrence-free survival was 99%, 90%, and 88%, respectively. Univariate analysis identified that age >52 years, positive lymph nodes, tumor grade 2, and Ki67 index >= 5% were statistically significant. Multivariate analysis identified that Ki67 index >= 5% (hazard ratio [HR], 4.69; 95% confidence interval [CI], 1.36-16.75, P=.015), positive lymph nodes (HR, 6.75; 95% CI, 1.73-24.43, P=.006) were independently associated with recurrence. The 5-year disease-free survival rate was 53% (95% CI, 14.20-91.81%) for patients with Ki-67 >= 5% or (and) positive lymph nodes, while 95% (95% CI, 82.26-100%) for the patients without these 2 factors. Ki67 index and lymph node status are independently associated with recurrence after resection of well-differentiated NF-PNETs in this study.
引用
收藏
页数:6
相关论文
共 29 条
[1]   Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study [J].
Ausania, F. ;
Senra del Rio, P. ;
Gomez-Bravo, M. A. ;
Martin-Perez, E. ;
Perez-Daga, J. A. ;
Dorcaratto, D. ;
Gonzalez-Nicolas, T. ;
Sanchez-Cabus, S. ;
Tardio-Baiges, A. .
PANCREATOLOGY, 2019, 19 (02) :367-371
[2]   The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After [J].
Bassi, Claudio ;
Marchegiani, Giovanni ;
Dervenis, Christos ;
Sarr, Micheal ;
Abu Hilal, Mohammad ;
Adham, Mustapha ;
Allen, Peter ;
Andersson, Roland ;
Asbun, Horacio J. ;
Besselink, Marc G. ;
Conlon, Kevin ;
Del Chiaro, Marco ;
Falconi, Massimo ;
Fernandez-Cruz, Laureano ;
Fernandez-Del Castillo, Carlos ;
Fingerhut, Abe ;
Friess, Helmut ;
Gouma, Dirk J. ;
Hackert, Thilo ;
Izbicki, Jakob ;
Lillemoe, Keith D. ;
Neoptolemos, John P. ;
Olah, Attila ;
Schulick, Richard ;
Shrikhande, Shailesh V. ;
Takada, Tadahiro ;
Takaori, Kyoichi ;
Traverso, William ;
Vollmer, Charles ;
Wolfgang, Christopher L. ;
Yeo, Charles J. ;
Salvia, Roberto ;
Buehler, Marcus .
SURGERY, 2017, 161 (03) :584-591
[3]   Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor [J].
Bettini, Rossella ;
Partelli, Stefano ;
Boninsegna, Letizia ;
Capelli, Paola ;
Crippa, Stefano ;
Pederzoli, Paolo ;
Scarpa, Aldo ;
Falconi, Massimo .
SURGERY, 2011, 150 (01) :75-82
[4]   Sporadic nonfunctioning pancreatic neuroendocrine tumors: Prognostic significance of incidental diagnosis [J].
Birnbaum, David Jeremie ;
Gaujoux, Sebastien ;
Cherif, Rim ;
Dokmak, Safi ;
Fuks, David ;
Couvelard, Anne ;
Vullierme, Marie-Pierre ;
Ronot, Maxime ;
Ruszniewski, Philippe ;
Belghiti, Jacques ;
Sauvanet, Alain .
SURGERY, 2014, 155 (01) :13-21
[5]   Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections [J].
Boninsegna, Letizia ;
Panzuto, Francesco ;
Partelli, Stefano ;
Capelli, Paola ;
Delle Fave, Gianfranco ;
Bettini, Rossella ;
Pederzoli, Paolo ;
Scarpa, Aldo ;
Falconi, Massimo .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (11) :1608-1615
[6]   Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors [J].
Castellano, Daniel ;
Grande, Enrique ;
Valle, Juan ;
Capdevila, Jaume ;
Reidy-Lagunes, Diane ;
Manuel O'Connor, Juan ;
Raymond, Eric .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) :1099-1114
[7]   Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors [J].
Cherenfant, Jovenel ;
Stocker, Susan J. ;
Gage, Mistry K. ;
Du, Hongyan ;
Thurow, Tiffany A. ;
Odeleye, Melanie ;
Schimpke, Scott W. ;
Kaul, Karen L. ;
Hall, Curtis R. ;
Lamzabi, Ihab ;
Gattuso, Paolo ;
Winchester, David J. ;
Marsh, Robert W. ;
Roggin, Kevin K. ;
Bentrem, David J. ;
Baker, Marshall S. ;
Prinz, Richard A. ;
Talamonti, Mark S. .
SURGERY, 2013, 154 (04) :785-791
[8]   Analysis of recurrence after the resection of pancreatic neuroendocrine tumors [J].
Chouliaras, Konstantinos ;
Newman, Naeem A. ;
Shukla, Mrinal ;
Swett, Katrina R. ;
Levine, Edward A. ;
Sham, Jonathan ;
Mann, Gary N. ;
Shen, Perry .
JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (03) :416-421
[9]   The Clavien-Dindo Classification of Surgical Complications Five-Year Experience [J].
Clavien, Pierre A. ;
Barkun, Jeffrey ;
de Oliveira, Michelle L. ;
Vauthey, Jean Nicolas ;
Dindo, Daniel ;
Schulick, Richard D. ;
de Santibanes, Eduardo ;
Pekolj, Juan ;
Slankamenac, Ksenija ;
Bassi, Claudio ;
Graf, Rolf ;
Vonlanthen, Rene ;
Padbury, Robert ;
Cameron, John L. ;
Makuuchi, Masatoshi .
ANNALS OF SURGERY, 2009, 250 (02) :187-196
[10]   ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors [J].
Falconi, M. ;
Eriksson, B. ;
Kaltsas, G. ;
Bartsch, D. K. ;
Capdevila, J. ;
Caplin, M. ;
Kos-Kudla, B. ;
Kwekkeboom, D. ;
Rindi, G. ;
Kloeppel, G. ;
Reed, N. ;
Kianmanesh, R. ;
Jensen, R. T. .
NEUROENDOCRINOLOGY, 2016, 103 (02) :153-171